DE69129269T2 - Verfahren zur herstellung von oligonukleotid-analogen die schwefel enthalten - Google Patents

Verfahren zur herstellung von oligonukleotid-analogen die schwefel enthalten

Info

Publication number
DE69129269T2
DE69129269T2 DE69129269T DE69129269T DE69129269T2 DE 69129269 T2 DE69129269 T2 DE 69129269T2 DE 69129269 T DE69129269 T DE 69129269T DE 69129269 T DE69129269 T DE 69129269T DE 69129269 T2 DE69129269 T2 DE 69129269T2
Authority
DE
Germany
Prior art keywords
oligonucleotide analogs
containing sulfur
analogs containing
producing oligonucleotide
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69129269T
Other languages
English (en)
Other versions
DE69129269D1 (de
Inventor
Wojciech Stec
Bogdan Uznanski
B Bergot
Bernard Hirschbein
Karen Fearon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lynx Therapeutics Inc
Original Assignee
Lynx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynx Therapeutics Inc filed Critical Lynx Therapeutics Inc
Publication of DE69129269D1 publication Critical patent/DE69129269D1/de
Application granted granted Critical
Publication of DE69129269T2 publication Critical patent/DE69129269T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
DE69129269T 1990-04-20 1991-02-14 Verfahren zur herstellung von oligonukleotid-analogen die schwefel enthalten Expired - Fee Related DE69129269T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/512,644 US5151510A (en) 1990-04-20 1990-04-20 Method of synethesizing sulfurized oligonucleotide analogs
PCT/US1991/001010 WO1991016331A1 (en) 1990-04-20 1991-02-14 Method of synthesizing sulfurized oligonucleotide analogs

Publications (2)

Publication Number Publication Date
DE69129269D1 DE69129269D1 (de) 1998-05-20
DE69129269T2 true DE69129269T2 (de) 1998-09-24

Family

ID=24039960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129269T Expired - Fee Related DE69129269T2 (de) 1990-04-20 1991-02-14 Verfahren zur herstellung von oligonukleotid-analogen die schwefel enthalten

Country Status (6)

Country Link
US (1) US5151510A (de)
EP (1) EP0524942B1 (de)
JP (1) JP3131840B2 (de)
AT (1) ATE165099T1 (de)
DE (1) DE69129269T2 (de)
WO (1) WO1991016331A1 (de)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
US5472881A (en) * 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
JPH09505465A (ja) * 1993-09-28 1997-06-03 ザ ジェネラル ホスピタル コーポレイション 神経増殖を調整し、β／Ａ４アミロイド誘発形態を逆転させる為のアンチセンスオリゴヌクレオチドの使用
GB9602326D0 (en) * 1996-02-06 1996-04-03 Cruachem Ltd Compounds
WO1997036005A1 (en) * 1996-03-26 1997-10-02 Lynx Therapeutics, Inc. Oligonucleotide treatments and compositions for human melanoma
US5852168A (en) * 1996-04-30 1998-12-22 Regents Of The University Of Minesota Sulfurization of phosphorus-containing compounds
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6172217B1 (en) * 1996-12-27 2001-01-09 Isis Pharmaceuticals Inc. Method of synthesizing phosphorothioate oligonucleotides
US5902881A (en) * 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6114519A (en) * 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6242591B1 (en) * 1997-10-15 2001-06-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized 2'-substituted oligonucleotides
US7273933B1 (en) * 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6069243A (en) * 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
US6184347B1 (en) 1998-11-19 2001-02-06 Agilent Technologies Inc. Minimization of blooming in high-density arrays by using reactive wash reagents
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
DE19906986C1 (de) * 1999-02-19 2000-07-13 Rhein Chemie Rheinau Gmbh Verfahren zur Herstellung von Dithiophosphorsäurepolysulfid-Gemischen und deren Verwendung
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
WO2002053596A2 (en) 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2002085924A2 (en) * 2001-04-23 2002-10-31 Abgenix, Inc. ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE
EP1414517A4 (de) * 2001-06-26 2008-02-06 Photomed Technologies Inc Mehrfach-wellenlängen-illuminator
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
JP2006505832A (ja) * 2002-02-26 2006-02-16 フアルマシア・コーポレーシヨン 配列決定システム計算機
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
EP1494714A4 (de) 2002-04-05 2008-03-05 Amgen Inc Humane anti-opgl-neutralisierende antikörper als selektive opgl-pfad-hemmer
IL164287A0 (en) * 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
EA018072B1 (ru) 2002-09-06 2013-05-30 Амджен Инк. Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
WO2004044132A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
RU2377253C2 (ru) 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
JP2006517786A (ja) * 2002-12-12 2006-08-03 ナノスフェアー　インコーポレイテッド 未増幅ｄｎａを用いた直接的ｓｎｐ検出
JP2006517191A (ja) * 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
JP2007524347A (ja) * 2003-02-27 2007-08-30 ナノスフェアー　インコーポレイテッド マイクロアレイ形式のアッセイにおける、万能ナノ粒子プローブを用いた標識不要の遺伝子発現プロファイリング
DK1613750T3 (en) 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
US20050250094A1 (en) * 2003-05-30 2005-11-10 Nanosphere, Inc. Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
JP2008501693A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
ATE501252T1 (de) 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EP2322215A3 (de) * 2004-07-16 2011-09-28 Pfizer Products Inc. Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper
EP1771583A2 (de) * 2004-07-26 2007-04-11 Nanosphere, Inc. Verfahren zur unterscheidung von methicillin-resistentem s. aureus von methicillin-sensitivem s. aureus in einer mischkultur
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923206B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
AU2005319404B2 (en) 2004-12-20 2011-10-20 Amgen Fremont Inc. Binding proteins specific for human Matriptase
PL1838733T3 (pl) 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
CA2590164A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
MX2007010971A (es) 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
US7807159B2 (en) * 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
WO2006125124A2 (en) * 2005-05-18 2006-11-23 Nanosphere, Inc. Substrate functionalization method for high sensitivity applications
DK1907583T4 (da) 2005-06-15 2020-01-27 Complete Genomics Inc Enkeltmolekyle-arrays til genetisk og kemisk analyse
US20070154903A1 (en) * 2005-06-23 2007-07-05 Nanosphere, Inc. Selective isolation and concentration of nucleic acids from complex samples
US20090270479A1 (en) * 2005-07-12 2009-10-29 Antonio Giordano Genetic and Epigenetic Alterations In the Diagnosis and Treatment of Cancer
NO345593B1 (no) 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
JP2009505106A (ja) * 2005-08-19 2009-02-05 ナノスフェアー インコーポレイテッド Ｄｎａ及び抗体を含むハイブリッド基板を調製するための方法及びその使用
PT2447283E (pt) 2005-09-07 2015-10-08 Pfizer Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
EP2548583A3 (de) 2005-11-10 2013-02-27 Curagen Corporation Verfahren zur behandlung von ovarial- und nierenkarzinom mit antikörpern gegen t-zell-immunglobulin-domänen- und mucin-domänen-1-(tim-1)-antigen
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
CA2630157C (en) 2005-12-07 2018-01-09 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
RS52357B (en) 2005-12-13 2012-12-31 Medimmune Limited BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2007133704A2 (en) * 2006-05-11 2007-11-22 Nanosphere, Inc. A non-nucleic acid based biobarcode assay for detection of biological materials
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
PL2511301T3 (pl) 2006-08-04 2018-05-30 Medimmune Limited Ludzkie przeciwciała do ErbB2
AU2007299705B2 (en) 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
RS56422B1 (sr) 2007-03-13 2018-01-31 Amgen Inc K-ras mutacije i terapija anti-egfr antitelom
PT2412828E (pt) 2007-03-13 2013-08-02 Amgen Inc Mutações k-ras e b-raf e terapia com anticorpos anti-egfr
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP3643782A1 (de) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modifizierte rnai-polynukleotide und verwendungen davon
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
MX348013B (es) 2009-05-05 2017-05-23 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos.
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
WO2011056215A1 (en) 2009-11-03 2011-05-12 Landers James P Versatile, visible method for detecting polymeric analytes
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
CN105131067B (zh) 2010-03-24 2019-02-19 雷克西制药公司 皮肤与纤维化症候中的rna干扰
EP3190187A1 (de) 2010-05-21 2017-07-12 Peptimed, Inc. Reagenzien und verfahren zur behandlung von krebs
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
EP2620428B1 (de) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetrische hilfsgruppe
AU2011323508B2 (en) 2010-11-01 2017-04-27 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
US8734790B2 (en) 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
WO2012118813A2 (en) 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
WO2013067098A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
KR20140076602A (ko) 2011-11-08 2014-06-20 화이자 인코포레이티드 항-m-csf 항체를 사용한 염증성 장애의 치료 방법
AU2012340174A1 (en) 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
NZ628314A (en) 2012-02-06 2017-01-27 Inhibrx Lp Cd47 antibodies and methods of use thereof
WO2013138518A1 (en) 2012-03-15 2013-09-19 Omeros Corporation Composition and method for diversification of target sequences
CN104540518A (zh) 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CA2903817A1 (en) 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3587592A1 (de) 2013-03-15 2020-01-01 Theranos IP Company, LLC Nukleinsäureamplifikation
CN116063479A (zh) 2013-06-04 2023-05-05 西托姆克斯治疗公司 用于缀合可活化抗体的组合物和方法
ES2683268T3 (es) 2013-07-25 2018-09-25 Cytomx Therapeutics, Inc. Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
PL3041958T3 (pl) 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
MX2016003957A (es) 2013-09-25 2017-02-02 Cytomx Therapeutics Inc Substratos de metaloproteinasas de matriz y otras porciones escindibles y metodos para usar los mismos.
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
EP3083684A1 (de) 2013-12-06 2016-10-26 NovImmune SA Antikörper gegen tlr4 und verfahren zur verwendung davon
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
JP6835586B2 (ja) 2014-01-31 2021-02-24 シトムクス セラピューティクス，インコーポレイティド マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
EP3137119B1 (de) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
EP3172235A2 (de) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3-antikörper, aktivierbare anti-cd3-antikörper, multispezifische anti-cd3-antikörper, multispezifische aktivierbare anti-cd3-antikörper und verfahren zur verwendung davon
US10111898B2 (en) 2014-08-27 2018-10-30 Peptimed, Inc. Anti-tumor compositions and methods
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
SG11201702682PA (en) 2014-10-03 2017-04-27 Cold Spring Harbor Lab Targeted augmentation of nuclear gene output
ES2823798T3 (es) 2014-12-31 2021-05-10 Dev Ct Biotechnology Anticuerpos humanizados específicos de alfa-enolasa y procedimientos de usos en la terapia del cáncer
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
LT3292149T (lt) 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
EP3292151A1 (de) 2015-05-04 2018-03-14 Cytomx Therapeutics Inc. Anti-itga3-antikörper, aktivierbare anti-itga3-antikörper und verfahren zur verwendung davon
EA201792414A1 (ru) 2015-05-04 2018-06-29 Сайтомкс Терапьютикс, Инк. Антитела против cd166, активируемые антитела против cd166 и способы их применения
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CN108135923B (zh) 2015-07-06 2021-03-02 菲奥医药公司 靶向超氧化物歧化酶1（sod1）的核酸分子
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
MX2018003454A (es) 2015-09-25 2018-08-15 Qiagen Sciences Llc Composiciones y metodos para diagnosticar la enfermedad de lyme y para predecir la eliminacion de las espiroquetas de la enfermedad de lyme despues del tratamiento.
CA3000971A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
JP7054675B2 (ja) 2015-12-14 2022-04-14 コールド スプリング ハーバー ラボラトリー 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法
EP3389725B1 (de) 2015-12-14 2022-04-06 Cold Spring Harbor Laboratory Zusammensetzungen und verfahren zur behandlung von erkrankungen des zentralen nervensystems
CA3005090A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
CA3005245A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of alagille syndrome
JP7049248B2 (ja) 2015-12-14 2022-04-06 コールド スプリング ハーバー ラボラトリー 常染色体優性精神遅滞－５とドラベ症候群の処置のためのアンチセンスオリゴマー
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN108883153A (zh) 2016-01-11 2018-11-23 印希比股份有限公司 多价和多特异性ox40结合融合蛋白
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN109310885B (zh) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b靶向抗体-药物缀合物及其使用方法
WO2018026969A2 (en) 2016-08-03 2018-02-08 Achaogen, Inc. Plazomicin antibodies and methods of use
MX2019004775A (es) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
WO2018160538A1 (en) 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
KR20190134654A (ko) 2017-03-09 2019-12-04 싸이톰스 테라퓨틱스, 인크. Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
PE20200616A1 (es) 2017-07-14 2020-03-11 Pfizer ANTICUERPOS CONTRA MAdCAM
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
AU2018322319B2 (en) 2017-08-25 2021-08-05 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
BR112020004231A2 (pt) 2017-08-30 2020-09-08 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
RS61596B1 (sr) 2017-10-14 2021-04-29 Abbvie Inc Anti-cd71 aktivirani konjugati leka-antitela i metode njihovog korišćenja
CA3078911A1 (en) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN111655729B (zh) 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
EP3773913A1 (de) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispezifische polypeptidkonstrukte mit eingeschränkter cd3 -bindung sowie verwandte verfahren und verwendungen
JP7360401B2 (ja) 2018-05-31 2023-10-12 グリコネックス インコーポレイテッド バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体
WO2020036867A1 (en) 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
CN113260383A (zh) 2018-11-02 2021-08-13 西托姆克斯治疗公司 可活化的抗cd166抗体及其使用方法
WO2020118109A2 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
EP3930761A1 (de) 2019-02-26 2022-01-05 CytomX Therapeutics, Inc. Kombinierte therapien aus aktivierbaren immunprüfpunktinhibitoren und konjugierten aktivierbaren antikörpern
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
EP4034171A1 (de) 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47-antikörper, aktivierbare anti-cd47-antikörper und verfahren zur verwendung davon
WO2021180821A2 (en) 2020-03-10 2021-09-16 Tiziana Life Sciences Plc Compositions of il-6/il-6r antibodies and methods of use thereof
KR20230005952A (ko) 2020-05-04 2023-01-10 임뮤노라이즌 엘티디. 전구체 삼중-특이적 항체 구조체 및 그의 이용 방법
US20230287410A1 (en) 2020-05-11 2023-09-14 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
EP4175982A1 (de) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralisierende antikörper gegen sars-coronavirus-2
EP4185322A2 (de) 2020-07-24 2023-05-31 Amgen Inc. Immunogene aus sars-cov2-spike-protein
WO2022120216A1 (en) 2020-12-04 2022-06-09 Qiagen Sciences Llc Compositions and methods for diagnosing sars-cov-2 (covid-19) and for monitoring sars-cov-2-specific immunological memory
IT202100003470A1 (it) 2021-02-16 2022-08-16 Fond Toscana Life Sciences Vaccines against sars-cov-2
WO2022221767A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023117965A1 (en) 2021-12-20 2023-06-29 Freie Universität Berlin Methods and agents for increasing rbm3 expression
WO2024073404A1 (en) 2022-09-28 2024-04-04 Sarepta Therapeutics, Inc. Pompe disease mouse model generation, characterization and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329892A1 (de) * 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
IL90359A0 (en) * 1988-05-26 1989-12-15 University Patents Inc Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and their production
US5194599A (en) * 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions

Also Published As

Publication number Publication date
EP0524942A1 (de) 1993-02-03
JPH05506015A (ja) 1993-09-02
EP0524942A4 (en) 1993-07-21
DE69129269D1 (de) 1998-05-20
EP0524942B1 (de) 1998-04-15
US5151510A (en) 1992-09-29
ATE165099T1 (de) 1998-05-15
WO1991016331A1 (en) 1991-10-31
JP3131840B2 (ja) 2001-02-05

Similar Documents

Publication Publication Date Title
DE69129269T2 (de) Verfahren zur herstellung von oligonukleotid-analogen die schwefel enthalten
DE69030745T2 (de) Verfahren und Reagens zur Sulfurierung von Organophosphiten
DE69132611T2 (de) Verfahren zur herstellung von sulfierte oligonukleotid-analoge
DE3874816D1 (de) Verfahren zur herstellung von cisplatin analogen verbindungen.
ATE266001T1 (de) Zur herstellung von sulfurierten oligonukleotidanaloga
EP0937732A3 (de) Verfahren zur Reduzierung der Sulfankettenlänge Bis(silylorganyl)polysulfanen
ES482641A1 (es) Procedimiento para la obtencion de esteres o bien esteramidas del acido 2-ciclopropil-pirimidin (4) il-(tiono)(tiol)- fosforico (fosfonico)
GB806638A (en) Organic derivatives of phosphoric acid
DE3583540D1 (de) Verfahren zur bekaempfung der varoatose bei bienen.
ES472670A1 (es) Procedimiento para la obtencion de diesteramidas de acido n-(aminometilen)-(mono- o bien ditio)-fosforico
US2976308A (en) Preparation of phosphorodithioate triesters
Stankiewicz et al. Reductive cleavage of the halogen–phosphorus and sulfur–phosphorus bonds with alkali metals
US5081272A (en) Process for preparation of phosphorodichlorothioates
DE69939190D1 (de) Verfahren für Arylalkylsulfid
ATE97417T1 (de) Verfahren zur herstellung von thiophosphorsaeure- dichloriden.
PT69861A (de) 2-cyclopropyl-pyrimidin(4)yl-(thiono) (thiol)-phosphor-(phosphon)-saureester bzw.-esteramide verfahren zu ihrer herstellung als insektizide und akarizide
US2857306A (en) Insecticidal materials
BR8107636A (pt) Composicoes inseticidas e acaricidas e processo para o combate de insetos e acaros
EG14088A (en) O-pyrazol-4-yl-o-ethyl-s-n-propyl-((thiono)-thiolphosphoric acid esters a process for their preparation and their use as agents for combating
US2865950A (en) Method of preparing o, o-dialkyl alkylthioalkyl phosphorothioates
ATE3770T1 (de) 4-trifluormethylphenyl-(d i)thiophosphorsaeureester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen.
ES459804A1 (es) Procedimiento para preparar derivados sustituidos de esterespiridizanilicos de acidos (tiono) (tiol)-fosforicos (fosfo- nicos).
AT333309B (de) Verfahren zur herstellung von neuen pyridazinyl(thiono) (thiol)-phosphor(phosphon)-saureestern bzw. -esteramiden
ATE3404T1 (de) Verfahren zur herstellung von 1,1-dihalogenalkenen.
Clifford Proposed Rules for Nomenclature for Compounds of Phosphorus, Sulfur, and Related Elements

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee